A unique model
IRIC, located in the heart of the Université de Montréal campus, operates according to a unique model in Canada that combines, under one roof, fundamental research activities, a university-level training program and a research maturation team. These generate discoveries that advance knowledge or that can quickly translate into new therapeutic solutions.
-
![]()
News A major federal grant for Delphine Bouilly, Sylvie Mader and Sébastien Lemieux’s laboratories
Delphine Bouilly’s team, in collaboration with Sylvie Mader and Sébastien Lemieux, has been awarded major funding from the Government of Canada’s New Frontiers in Research Fund – Exploration Stream, for her project “Exploiting Electrolytic Gating in Graphene Field-Effect Nanosensors to Achieve Multiplexed Breast Cancer Profiling for Personalized Medicine”.
-
![]()
News Two IRIC researchers receive funding from the Natural Sciences and Engineering Research Council of Canada (NSERC)
In 2025, as part of the Discovery Grants Program, NSERC awarded significant five-year funding to the team led by Philippe Roux, head of the Cell Signalling and Proteomics Research Unit, and to the team led by Matthew Smith, head of the Cancer Signalling and Structural Biology Research Unit.
-
![]()
News Marc Therrien elected member of the Canadian Academy of Health Sciences
Marc Therrien, Principal Investigator in the Intracellular Signalling Research Unit and Chief Executive Officer of IRIC, as well as Full Professor in the Department of Pathology and Cell Biology at the Faculty of Medicine of the Université de Montréal, joins the Canadian Academy of Health Sciences (CAHS) as a new member. A total of 47 new members have been elected to the CAHS for the year 2025.
-
![]()
News IRIC highlights the scientific knowledge of the next generation!
The 7th edition of IRIC’s 2025 Summer Interns’ Scientific Day was held on Thursday, August 7.
-
![]()
News Behind-the-scenes work brought to light: CIHR award for investigators Gregory Emery and David Knapp
Gregory Emery and David Knapp, directors of the IRIC Vesicular Trafficking and Cell Signalling Research Unit and Cellular Engineering Research Unit, respectively, have both received a special mention for outstanding contribution from the Canadian Institutes of Health Research (CIHR) College of Reviewers. In addition, Gregory Emery was recognized for his outstanding evaluation services during three or more consecutive project grant competitions, a distinction awarded to only 1% of evaluators nationwide. David Knapp received three citations for outstanding contribution. This recognition reflects the remarkable quality of their evaluation work and their constructive participation in committee discussions.
-
![]()
News Unmutated tumor antigens: exploitable targets for immunotherapy
The team headed by Claude Perreault, Director of IRIC’s Immunobiology Research Unit, has identified novel tumor antigens that could lead to the development of vaccines for the treatment of two cancers: melanoma and non-small cell lung cancer. To achieve this, the team led by PhD student Anca Apavaloaei has adopted an unbiased approach that examines all genetic material, including DNA described as “junk” because it is not coding for any known protein. The work, the fruit of collaborations with the Epitopea company, McGill University, the University of Liège and the University of Lausanne, has been published in the journal Nature Cancer.
